Search results
Showing 1606 to 1620 of 7711 results
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Show all sections
Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.
Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer in adults after complete tumour resection.
Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.
Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Evidence-based recommendations on using dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome or atrioventricular block.
NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA923
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728
Awaiting development [GID-TA11071] Expected publication date: TBC
Evidence-based recommendations on AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images
Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis
Tests in secondary care to identify people at high risk of ovarian cancer (DG31)
Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G)
Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the